These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 19914543)

  • 41. Genetically modified tumour vaccines--where we are today.
    Nawrocki S; Mackiewicz A
    Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
    Xia D; Moyana T; Xiang J
    Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sperm-associated antigens as targets for cancer immunotherapy: expression pattern and humoral immune response in cancer patients.
    Siliņa K; Zayakin P; Kalniņa Z; Ivanova L; Meistere I; Endzeliņš E; Abols A; Stengrēvics A; Leja M; Ducena K; Kozirovskis V; Linē A
    J Immunother; 2011 Jan; 34(1):28-44. PubMed ID: 21150711
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.
    Aguilar LK; Guzik BW; Aguilar-Cordova E
    J Cell Biochem; 2011 Aug; 112(8):1969-77. PubMed ID: 21465529
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HER-2/neu as a target for cancer vaccines.
    Baxevanis CN; Voutsas IF; Gritzapis AD; Perez SA; Papamichail M
    Immunotherapy; 2010 Mar; 2(2):213-26. PubMed ID: 20635929
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of HER2/ neu-derived peptides capable of inducing both cellular and humoral immune responses in HLA-A24 positive breast cancer patients.
    Azuma K; Shichijo S; Shomura H; Matsueda S; Fujii T; Itoh K
    Breast Cancer Res Treat; 2004 Jul; 86(1):19-29. PubMed ID: 15218358
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy.
    Yuan S; Shi C; Liu L; Han W
    Expert Opin Biol Ther; 2010 Jul; 10(7):1037-48. PubMed ID: 20420512
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tumor specific CD8+ T cells in patients with lung cancer and healthy individuals.
    Karanikas V; Germenis A
    J BUON; 2009 Sep; 14 Suppl 1():S153-7. PubMed ID: 19785058
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenic antigens as therapeutic targets against myeloid leukaemic cells.
    Hofmann S; Greiner J
    Leuk Res; 2010 Jul; 34(7):850-1. PubMed ID: 20359745
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A new era in anticancer peptide vaccines.
    Perez SA; von Hofe E; Kallinteris NL; Gritzapis AD; Peoples GE; Papamichail M; Baxevanis CN
    Cancer; 2010 May; 116(9):2071-80. PubMed ID: 20187092
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Towards a therapeutic breast cancer vaccine: the next steps.
    Emens LA
    Expert Rev Vaccines; 2005 Dec; 4(6):831-41. PubMed ID: 16372879
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.
    Monjazeb AM; Hsiao HH; Sckisel GD; Murphy WJ
    J Immunotoxicol; 2012; 9(3):248-58. PubMed ID: 22734880
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunogenic HER-2/neu peptides as tumor vaccines.
    Baxevanis CN; Sotiriadou NN; Gritzapis AD; Sotiropoulou PA; Perez SA; Cacoullos NT; Papamichail M
    Cancer Immunol Immunother; 2006 Jan; 55(1):85-95. PubMed ID: 15948002
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunoprevention and immunotherapy of mammary carcinoma.
    Lollini PL; Nicoletti G; Landuzzi L; De Giovanni C; Nanni P
    Breast J; 2010; 16 Suppl 1():S39-41. PubMed ID: 21050308
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cancer therapy and vaccination.
    Aly HA
    J Immunol Methods; 2012 Aug; 382(1-2):1-23. PubMed ID: 22658969
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cancer vaccines. Any future?
    Myc LA; Gamian A; Myc A
    Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):249-59. PubMed ID: 21644030
    [TBL] [Abstract][Full Text] [Related]  

  • 58. AE37: a novel T-cell-eliciting vaccine for breast cancer.
    Sears AK; Perez SA; Clifton GT; Benavides LC; Gates JD; Clive KS; Holmes JP; Shumway NM; Van Echo DC; Carmichael MG; Ponniah S; Baxevanis CN; Mittendorf EA; Papamichail M; Peoples GE
    Expert Opin Biol Ther; 2011 Nov; 11(11):1543-50. PubMed ID: 21895539
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dendritic cell-based vaccines: clinical applications in breast cancer.
    Gelao L; Criscitiello C; Esposito A; De Laurentiis M; Fumagalli L; Locatelli MA; Minchella I; Santangelo M; De Placido S; Goldhirsch A; Curigliano G
    Immunotherapy; 2014; 6(3):349-60. PubMed ID: 24762078
    [TBL] [Abstract][Full Text] [Related]  

  • 60. DNA vaccine for cancer immunotherapy.
    Yang B; Jeang J; Yang A; Wu TC; Hung CF
    Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.